The MET gene gives cells instructions for a surface protein that helps them respond to growth and repair signals. If this signaling is too weak or too strong, cells may not grow, move, or heal in the usual way, and certain variants or extra copies of the gene can contribute to some cancers. In medicine, this gene is important because it helps regulate normal development, tissue repair, and cell survival. MET is better known in cancer care than in popular culture and has had little celebrity-driven public attention.
What is a gene?
Genes are stretches of DNA that carry instructions your cells use to make molecules or regulate processes in the body. Some genes hold the information needed to make proteins, the parts of cells that do the work. Others mostly help control when certain processes happen, where they happen, and how strongly they are carried out. As a group, genes affect how the body develops and works, and they can influence how you respond to food, stress, or medicines. For a more detailed look at this subject, you can find more in the LearnHub.
Overview
METGene function
What if the gene works
The MET gene helps cells respond to growth signals. It supports normal cell growth, movement, and tissue repair during development and healing.
Risk
What if the gene does not work
Certain variants in the MET gene can drive extra growth signaling, most notably increasing the chance of papillary kidney cancer; other MET changes appear in lung and other cancers. Effects vary by variant, from milder changes to more disruptive ones.
Treatment
What does that mean for your treatment
For variants in the MET gene, treatment choices are mainly guided by activating tumor changes rather than loss-of-function changes. MET exon 14 skipping can make MET-targeted drugs such as capmatinib or tepotinib relevant, and high-level amplification of the MET gene may also support a MET inhibitor in some settings.
Conditions associated with MET
Gene function
What if the gene works
Your cells use the MET gene to read growth and movement cues from their surroundings. This helps tissues form in an organized way and supports normal renewal and healing. In simple terms, the MET gene helps cells know when to grow, stay in place, or move to where they are needed.
The MET gene makes a cell surface receiver that picks up hepatocyte growth factor, a messenger protein that tells cells how to respond. This lets cells react to nearby cues rather than acting on their own.
When this signal arrives, the MET gene helps turn on pathways that support controlled cell growth and cell survival. This is part of how the MET gene helps cells grow and move during normal tissue upkeep.
The MET gene helps some cells loosen their attachments and travel to a new spot when movement is needed. This supports tissue shaping during development and coordinated repair in adult life.
Its protein helps groups of cells organize into layered and branched structures instead of growing as a simple flat sheet. That pattern is important as organs take shape and maintain their usual structure.
What is a variant?
A genetic variant is a minor change in a gene’s DNA sequence. These changes are common and help shape normal human diversity, including differences in appearance, metabolism, or the way the body responds to environmental influences. Many variants do not cause any noticeable effect and are simply part of natural genetic variation. In some situations, though, a variant changes how a gene works more significantly and may contribute to or cause a genetic condition.
Genetic variants
What if the gene does not work
Changes in the MET gene can alter how the receptor is shaped, how strongly it signals, or how quickly the cell clears it away. Some variants mildly shift signaling, while more disruptive variants can keep the receptor switched on for too long or, less often, reduce its stability or activity. This is how variants in the MET gene affect cell signaling, and why their impact can vary. Stronger activating variants are linked to earlier or larger effects in MET-related cancers.
How variants are linked to conditions
Variants of the MET gene are most clearly linked to hereditary papillary renal cell carcinoma, an inherited kidney cancer syndrome that can run in families. Pathogenic variants in the MET gene can cause this condition and may confirm the diagnosis in the right clinical setting. Separate, noninherited changes in the MET gene are also found in some cancers, especially non-small cell lung cancer, where they help classify the tumor rather than predict a healthy person’s future cancer risk.
A variant is not necessarily a diagnosis
Variants in genes are a usual feature of human biology and are widely found in the general population. Most do not directly affect health and instead reflect normal human diversity. For many genes, having a variant associated with a condition points to a possible link rather than a firm diagnosis, especially when several genes and environmental factors contribute. In some situations, though, one well-characterized variant in a particular gene can be enough to confirm a diagnosis.
Are there things that can increase or change my risk?
For inherited harmful changes in the MET gene, the gene change itself is the main reason risk is higher, especially for a form of kidney cancer, and risk often rises with age. There is not enough evidence to say that lifestyle changes lower this inherited risk, so regular monitoring is usually the most important step.
Inheritance of MET variants
For families asking how variants of the MET gene are inherited, the best-established pattern is autosomal dominant for hereditary papillary renal cell carcinoma linked to inherited MET variants. This means a parent carrying a disease-causing variant in one copy of the MET gene can pass it to a child, with a 50% chance in each pregnancy. Sons and daughters can inherit it equally, and either parent can pass it on. Not everyone who inherits a MET variant will be affected in exactly the same way.
What does my MET result mean for my family?
Some MET results are linked to an inherited kidney cancer risk that can run in families in a dominant pattern, which means close relatives such as parents, brothers, sisters, and children may also carry the same change. For many families, this means first-degree relatives may want to consider genetic counseling and, in some cases, testing. Relatives who carry the change may benefit from kidney monitoring over time.
Genetic information
Genetic testing
How you find out about variants
MET genetic testing looks for changes in the MET gene using a blood, saliva, or tumor sample. A lab reads the DNA to check for inherited variants or cancer related changes such as MET exon 14 skipping or extra copies of the gene. Results can show a clearly relevant variant, no variant, or a finding that needs more interpretation.
When should I consider getting a genetic test?
Testing may be worth discussing if several close relatives have had a rare type of kidney cancer, especially papillary kidney cancer, or if kidney cancer appeared at a young age. In those families, an inherited change in the MET gene can sometimes explain the pattern and help guide care for relatives.
A genetic result is only one part of your health story
Genetic test results can provide useful insight, but how much they reveal depends on the condition and on the kind of variant involved. Over time, many factors shape how the body functions, including lifestyle, environment, age, and medical history. For some conditions, particularly those affected by multiple genes, genetic information offers context rather than certainty and makes the most sense when considered with the rest of a person’s care. In other situations, a genetic result can give a clear answer. In areas like medication response, these results can also help put individual experiences into context.
Pharmacogenetics
How variants shape your response to medicine
Genetic variation can affect how people respond to medicines. Some people break down a drug more quickly, while others process it more slowly or react more strongly to the same dose. This helps explain why one treatment can work well for one person but cause more side effects or less benefit in another. These differences are common and are one part of the bigger picture, along with age, kidney and liver function, other medicines, and overall health.
What is Pharmacogenetics?
Pharmacogenetics examines how genetic differences shape the way a person responds to medications. By studying links between genes and drugs, it helps explain why treatments work differently from one person to another. For many medicines, genes influence both how strongly a drug works and how the body processes it. This information can support treatment decisions that are more informed and more individualized. More detail on this topic is available in the LearnHub.
Drugs influenced by the MET gene
When should I seek medical advice?
There is not yet a broadly confirmed role for inherited changes in this gene in predicting how most medicines will work, so general medication questions are best discussed with your doctor. MET is different in cancer care: changes found in the cancer itself, rather than inherited changes, can sometimes affect treatment choices and are worth discussing with your oncology team.
History
The MET gene entered cancer research in the 1980s, when scientists identified it as part of an abnormal gene fusion in cells exposed to a laboratory carcinogen. Initially understood only through visible traits, later recognized as tied to a specific gene, this finding helped place the MET gene among the early human cancer related genes. From these first observations, research expanded steadily. In the 1990s and 2000s, studies linked changes in the MET gene to several cancers, especially papillary kidney cancer and later some lung cancers. That history became especially important as drug development moved toward treatments matched to specific gene variants. Today, the MET gene is well known in precision cancer medicine because its discovery helped shape how tumors are classified and treated.